Fierce Biotech May 24, 2024
Zealand Pharma’s GLP-1/GLP-2 receptor dual agonist may have only managed at best an average 4.3% reduction in weight loss when given in low doses, but the Danish company is keen to stress that higher doses are where the drug should prove its worth.
The 54-person phase 2 trial involved administering either 4-mg weekly subcutaneous doses of dapiglutide, a 6-mg dose or placebo over 12 weeks. Participants who received 4 mg saw an average weight loss of 2.9%, barely above the 2.2% seen in the placebo cohort. The 6-mg group saw a slightly larger weight loss of 4.3%. No lifestyle interventions were part of the trial.
Drilling down into the numbers, both missed statistical significance, with the lowest dose hitting a...
Today's Sponsors
Today's Sponsor